Gefitinib, sold under the brand name Iressa, is a medication used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib...
21 KB (2,162 words) - 15:09, 19 August 2024
this case, Gefitinib is the inhibitor of tyrosine kinase. Incorrect tyrosine kinase function can lead to non-small cell lung cancer. Gefitinib is a tyrosine...
43 KB (5,251 words) - 10:44, 24 June 2024
Quinazoline (section Gefitinib)
the U.S. Food and Drug Administration (FDA) approved the quinazoline gefitinib. The drug, produced by AstraZeneca, is an inhibitor of the protein kinase...
14 KB (1,240 words) - 01:14, 27 July 2024
Irinotecan Topotecan Etoposide Teniposide Tafluposide Bortezomib Erlotinib Gefitinib Imatinib Vemurafenib Vismodegib Azacitidine Azathioprine Capecitabine...
5 KB (324 words) - 12:07, 20 July 2024
for bronchorrhea vary depending on the inciting cause; they include: gefitinib - epidermal growth factor receptor tyrosine kinase inhibitor indomethacin...
7 KB (786 words) - 04:15, 17 June 2024
factor receptor inhibitor (EGFR inhibitor). The drug follows Iressa (gefitinib), which was the first drug of this type. Erlotinib specifically targets...
22 KB (1,993 words) - 23:37, 23 March 2024
Methylphenidate and dextroamphetamine-induced peripheral vasculopathy Gefitinib Obstruction of capillaries: Cryoglobulinaemia – proteins in the blood...
25 KB (2,529 words) - 17:34, 12 September 2024
first generation tyrosine-kinase inhibitors (TKIs) like erlotinib or gefitinib, but also against less common mutations which are resistant to these drugs...
15 KB (1,122 words) - 15:16, 4 August 2024
imatinib may be effective in treatment of dermatofibrosarcoma protuberans. Gefitinib (Iressa, also known as ZD1839), targets the epidermal growth factor receptor...
20 KB (2,234 words) - 01:21, 22 July 2024
the frequency and amplitude modulated, they applied the EGFR inhibitor gefitinib or the highly selective MAPK/ERK kinase (MEK) inhibitor PD0325901 (PD)...
24 KB (3,068 words) - 07:21, 7 June 2024
therapeutics directed against EGFR (called "EGFR inhibitors", EGFRi), including gefitinib, erlotinib, afatinib, brigatinib and icotinib for lung cancer, and cetuximab...
60 KB (6,879 words) - 14:26, 16 July 2024
lung cancer (NSCLC), EGFR-specific tyrosine kinase inhibitors such as gefitinib have shown limited therapeutic success. This resistance is proposed to...
18 KB (2,105 words) - 01:40, 20 August 2024
first-line treatment with other EGFR tyrosine kinase inhibitors, such as gefitinib, erlotinib, and afatinib. In the US, EGFR exon 19 deletions, exon 21 L858R...
17 KB (1,559 words) - 21:20, 27 September 2024
potential to metastasize. 2005: Dana–Farber scientists report that the drug gefitinib (Iressa) produces dramatic benefits in non-small cell lung cancer patients...
20 KB (2,046 words) - 01:46, 21 September 2024
pathway upregulation was observed and after inhibition of this pathway by gefitinib tumor growth was decreased both in vitro and in vivo. Sarilumab was approved...
12 KB (1,289 words) - 19:20, 4 December 2023
osimertinib, erlotinib, gefitinib, afatinib, or dacomitinib – with osimertinib known to be superior to erlotinib and gefitinib, and all superior to chemotherapy...
90 KB (9,784 words) - 14:55, 18 September 2024
the tumor cells. Various targeted agents, such as imatinib, cetuximab, gefitinib, trastuzumab, had been used for exploring new treatment for salivary gland...
19 KB (1,998 words) - 07:13, 6 May 2024
alterations in lung adenocarcinomas. First-generation EGFR TKIs, including gefitinib and erlotinib, have been shown to be more effective in treating EGFR-mutated...
42 KB (4,603 words) - 02:26, 2 September 2024
in the preparation of the antibiotic linezolid, the anticancer agent gefitinib (brand name Iressa) and the analgesic dextromoramide. In research and...
10 KB (786 words) - 00:52, 30 June 2024
Laight A, McKillop D, et al. (2005). "Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol". Clinical Pharmacokinetics...
31 KB (2,634 words) - 22:05, 30 August 2024
a double-blind, head-to-head phase III study comparing icotinib with gefitinib in 399 patients across 27 centers in China. Results showed icotinib to...
7 KB (668 words) - 14:07, 16 December 2022
designation. Early results of a phase I trial combining durvalumab and gefitinib in participants with lung cancer "showed promise". A phase I clinical...
28 KB (2,721 words) - 04:14, 1 October 2024
inhibitors: Afatinib Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154...
68 KB (5,999 words) - 20:41, 31 August 2024
trials continued. In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced. Dacomitinib was approved...
6 KB (289 words) - 02:02, 15 September 2024
are alternatives, including quality-assured biosimilars Afatinib and gefitinib are alternatives Pembrolizumab is an alternative, including quality-assured...
67 KB (4,835 words) - 05:59, 17 August 2024
sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol...
53 KB (4,975 words) - 03:43, 30 September 2024
"Fairfax-plus" site in North Wilmington, Delaware. In 2002, its drug Iressa (gefitinib) was approved in Japan as monotherapy for non-small cell lung cancer....
86 KB (7,963 words) - 18:33, 12 September 2024
imatinib was developed against chronic myelogenous leukemia (CML) and later gefitinib and erlotinib aiming at the EGF receptor. Dasatinib is a Src tyrosine...
10 KB (1,179 words) - 18:31, 8 August 2024
inhibitors: Afatinib Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154...
93 KB (8,729 words) - 21:31, 30 September 2024
sodium Durvalumab Eculizumab Esomeprazole Exenatide FluMist Fulvestrant Gefitinib Glycopyrronium bromide/formoterol Goserelin Isosorbide mononitrate Metoprolol...
42 KB (3,486 words) - 00:32, 30 September 2024